SYNH Key Statistics, Chart & Performance
The current stock price of SYNH is 42.98 USD. In the past month the price increased by 0.7%. In the past year, price decreased by -8.84%.
SYNH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.63 | 232.51B | ||
| DHR | DANAHER CORP | 30.92 | 168.37B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 200.78 | 61.01B | ||
| A | AGILENT TECHNOLOGIES INC | 26.62 | 42.11B | ||
| IQV | IQVIA HOLDINGS INC | 20.84 | 41.28B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.5 | 30.34B | ||
| WAT | WATERS CORP | 31.24 | 23.62B | ||
| ILMN | ILLUMINA INC | 32.36 | 21.56B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.97 | 19.82B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.61 | 16.76B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B | ||
| TEM | TEMPUS AI INC | N/A | 11.79B |
Related stock screener links
About SYNH
Company Profile
Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
Company Info
SYNEOS HEALTH INC
1030 Sync Street
Morrisville NORTH CAROLINA 27560 US
CEO: Alistair Macdonald
Employees: 28768
Phone: 19198769300.0
SYNEOS HEALTH INC / SYNH FAQ
What does SYNEOS HEALTH INC do?
Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
What is the stock price of SYNEOS HEALTH INC today?
The current stock price of SYNH is 42.98 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of SYNEOS HEALTH INC?
SYNH does not pay a dividend.
What is the ChartMill technical and fundamental rating of SYNH stock?
SYNH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Would investing in SYNEOS HEALTH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SYNH.
What is SYNEOS HEALTH INC worth?
SYNEOS HEALTH INC (SYNH) has a market capitalization of 4.46B USD. This makes SYNH a Mid Cap stock.
SYNH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SYNH. When comparing the yearly performance of all stocks, SYNH turns out to be only a medium performer in the overall market: it outperformed 45.73% of all stocks.
SYNH Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SYNH. SYNH has an average financial health and profitability rating.
SYNH Financial Highlights
Over the last trailing twelve months SYNH reported a non-GAAP Earnings per Share(EPS) of 3.78. The EPS decreased by -23.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.31% | ||
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| Debt/Equity | 0.77 |
SYNH Forecast & Estimates
16 analysts have analysed SYNH and the average price target is 43.35 USD. This implies a price increase of 0.86% is expected in the next year compared to the current price of 42.98.
For the next year, analysts expect an EPS growth of -25.43% and a revenue growth -2.82% for SYNH